循环肿瘤DNA检测在放疗中的研究进展

doi:10.3760/cma.j.issn.1673-422X.2018.06.007

摘要/Abstract

摘要： 循环肿瘤DNA（ctDNA）是位于外周循环的游离肿瘤DNA片段，携带来源于肿瘤的生物遗传学信息。近年来二代测序技术的革新拓展了ctDNA分析在临床中的应用前景，ctDNA检测在放疗领域已取得较大进展，特别是在评价放疗敏感性方面。外周血中的ctDNA具有提取方便、检测特异性高等特点。检测ctDNA不仅有利于发现微小残留病灶和肿瘤转移，而且有助于临床医生更好地进行放疗后的疗效评价和预后判断，将为恶性肿瘤的诊疗策略提供新思路。

关键词: 放射疗法, 肿瘤, 生物学标记, 预后, 循环肿瘤DNA

Abstract: Circulating tumor DNA (ctDNA) refers to the DNA segment of the free tumor located in the peripheral circulation, which carries the biologic information derived from the tumor. In recent years, the innovation of the second generation sequencing technology has expanded the prospect of the clinical application of ctDNA analysis. Detection of ctDNA has made a great progress in the field of radiation therapy, especially in the aspect of evaluating the sensitivity of radiotherapy. ctDNA in peripheral blood is characterized by convenient extraction and high specificity. Detection of ctDNA is not only conducive to find minimal residual disease and metastasis, but also help clinicians better evaluate the curative effect and judge prognosis after radiotherapy, which will provide a new way of thinking for the diagnosis and treatment strategy of tumor.

Key words: Radiotherapy, Neoplasms, Biological markers, Prognosis, Circulating tumor DNA

王拓，李桂香. 循环肿瘤DNA检测在放疗中的研究进展[J]. 国际肿瘤学杂志, 2018, 45(6): 352-354.

Wang Tuo, Li Guixiang. Research progress of circulating tumor DNA detection in radiotherapy[J]. Journal of International Oncology, 2018, 45(6): 352-354.

参考文献

［1］ Baumann M, Krause M, Overgaard J, et al. Radiation oncology in the era of precision medicine［J］. Nat Rev Cancer, 2016, 16(4): 234-249. DOI: 10.1038/nrc.2016.18. ［2］刘斌亮. 循环肿瘤DNA在乳腺癌内分泌治疗耐药中的应用［J］. 国际肿瘤学杂志, 2017, 44(10): 779-782. DOI: 10.3760/cma.j.issn.1673-422X.2017.10.014. ［3］ Yao W, Mei C, Nan X, et al. Evaluation and comparison of in vitro degradation kinetics of DNA in serum, urine and saliva: a qualitative study［J］. Gene, 2016, 590(1): 142-148. DOI: 10.1016/j.gene.2016.06.033. ［4］ Ulrich BC, Paweletz CP. Cellfree DNA in oncology: gearing up for clinic［J］. Ann Lab Med, 2018, 38(1): 18. DOI: 10.3343/alm.2018.38.1.1. ［5］ Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early and latestage human malignancies［J］. Sci Transl Med, 2014, 6(224): 224ra24. DOI: 10.1126/ scitranslmed.3007094. ［6］ Zhao L, Fong AHW, Liu N, et al. Molecular subtyping of nasopharyngeal carcinoma (NPC) and a microRNAbased prognostic model for distant metastasis［J］. J Biomed Sci, 2018, 25(1): 16. DOI: 10.1186/s1292901804175. ［7］ Chen QY, Guo SY, Tang LQ, et al. Combination of tumor volume and EpsteinBarr virus DNA improved prognostic stratification of stage Ⅱ nasopharyngeal carcinoma in the IMRT era: a largescale cohort study［J］. Cancer Res Treat, 2017, In press. DOI: 10.4143/crt.2017.237. ［8］ Chen M, Yin L, Wu J, et al. Impact of plasma EpsteinBarr virusDNA and tumor volume on prognosis of locally advanced nasopharyngeal carcinoma［J］. Biomed Res Int, 2015, 2015: 617949. DOI: 10.1155/2015/ 617949. ［9］ Chen WH, Tang LQ, Guo SS, et al. Prognostic value of plasma EpsteinBarr virus DNA for local and regionally advanced nasopharyngeal carcinoma treated with cisplatinbased concurrent chemoradiotherapy in intensitymodulated radiotherapy era［J］. Medicine (Baltimore), 2016, 95(5): e2642. DOI: 10.1097/MD.0000000000002642. ［10］ Ben Lassoued A, Nivaggioni V, Gabert J. Minimal residual disease testing in hematologic malignancies and solid cancer［J］. Expert Rev Mol Diagn, 2014, 14(6): 699-712. DOI: 10.1586/14737159.2014.927311. ［11］ Ahn SM, Chan JY, Zhang Z, et al. Saliva and plasma quantitative polymerase chain reactionbased detection and surveillance of human papillomavirusrelated head and neck cancer［J］. JAMA Otolaryngol Head Neck Surg, 2014, 140(9): 846-854. DOI: 10.1001/jamaoto.2014.1338. ［12］ Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage［J］. Nat Med, 2014, 20(5): 548-554. DOI: 10.1038/nm.3519. ［13］ Chaudhuri AA, Binkley MS, Osmundson EC, et al. Predicting radiotherapy responses and treatment outcomes through analysis of circulating tumor DNA［J］. Semin Radiat Oncol, 2015, 25(4): 305-312. DOI: 10.1016/j.semradonc.2015.05.001. ［14］ Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer［J］. N Engl J Med, 2013, 368(13): 1199-1209. DOI: 10.1056/ NEJMoa1213261. ［15］ Bidard FC, Madic J, Mariani P, et al. Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma［J］. Int J Cancer, 2014, 134(5): 1207-1213. DOI: 10.1002/ijc.28436. ［16］ Dahlstrom KR, Li G, Hussey CS, et al. Circulating human papillomavirus DNA as a marker for disease extent and recurrence among patients with oropharyngeal cancer［J］. Cancer, 2015, 121(19): 34553464. DOI: 10.1002/cncr.29538. ［17］ JamalHanjani M, Wilson GA, McGranahan N, et al. Tracking the evolution of nonsmallcell lung cancer［J］. N Engl J Med, 2017, 376(22): 2109-2121. DOI: 10.1056/ NEJMoa1616288. ［18］ Jeong Y, Hoang NT, Lovejoy A, et al. Role of KEAP1/NRF2 and TP53 mutations in lung squamous cell carcinoma development and radiation resistance［J］. Cancer Discov, 2017, 7(1): 86-101. DOI: 10.1158/ 2159-8290.CD160127. ［19］ Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts earlystage lung cancer evolution［J］. Nature, 2017, 545(7655): 446-451. DOI: 10.1038/nature22364.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[3]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[4]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[5]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[6]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[7]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[8]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[9]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[10]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[11]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[12]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[13]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[14]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[15]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.